

Arden and Greater East Midlands Commissioning Support Unit in association with
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from June 2015

For further details see *PACE Bulletin* Volume 9 No 11 (July 2015)

Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Amlodipine 5mg and 10mg tablets (generic)	For the treatment of hypertension.	GREEN Included in the Lincolnshire Joint Formulary for first line use in hypertension.
Budesonide 3mg gastro-resistant capsules (Budenofalk) (Dr Falk)	For the induction of remission in patients with mild to moderate active Crohn's disease affecting the ileum and/or the ascending colon. For the symptomatic relief of chronic diarrhoea due to collagenous colitis. For autoimmune hepatitis.	AMBER without shared care – first line. Included in the Lincolnshire Joint Formulary
Budesonide 9mg gastro-resistant granules (Budenofalk Granules) (Dr Falk)	For the induction of remission in patients with mild to moderate active Crohn's disease affecting the ileum and/or the ascending colon. For the symptomatic relief of chronic diarrhoea due to collagenous colitis.	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Budesonide 3mg gastro-resistant sustained release capsules (Entocort CR) (AstraZeneca)	For the induction of remission in patients with mild to moderate Crohn's disease affecting the ileum and/or the ascending colon.	AMBER without shared care – second line after Budenofalk. Included in the Lincolnshire Joint Formulary
Budesonide 9mg sustained release gastro-resistant tablets (Cortiment) (Ferring)	For the induction of remission in mild to moderate active ulcerative colitis, where mesalazine is not sufficient.	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Felodipine 2.5mg, 5mg and 10mg modified release tablets (generic)	For the treatment of hypertension.	GREEN Included in the Lincolnshire Joint Formulary for second line use in hypertension.
Felodipine 5mg and 10mg modified release tablets (Vascalpha)	For the treatment of hypertension.	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary for this indication.
Gliclazide modified release tablets 30mg and 60mg (Vamju) (Amdipharm Mercury)	For the treatment of type 2 diabetes mellitus	GREEN Approved for inclusion in the Lincolnshire Joint Formulary. Second line sulfonylurea for consideration in those intolerant to gliclazide tablets 80mg.
Lecicarbon C suppositories (containing sodium hydrogen carbonate 250mg and sodium dihydrogen phosphate 340mg per suppository) (Aspire Pharma)	For constipation, bowel clearance and diagnostic procedures in children under 12 years	RED-RED. Not approved for inclusion in the Lincolnshire Joint Formulary.

Lercanidipine 10mg and 20mg tablets (generic)	For mild to moderate hypertension	GREEN Included in the Lincolnshire Joint Formulary for first line use for mild to moderate hypertension.
Macrogol (polyethylene glycol) 3350 13.125g plus electrolytes powder for oral solution (CosmoCol) (Stirling Anglian)	For chronic constipation and faecal impaction in adults, the elderly and adolescents. Not recommended for children under 12 years.	GREEN Approved for inclusion in the Lincolnshire Joint Formulary
Macrogol (polyethylene glycol) 3350 6.9g plus electrolytes powder for oral solution (CosmoCol Half) (Stirling Anglian)	For chronic constipation and faecal impaction in adults, the elderly and adolescents. Not recommended for children under 12 years.	GREEN Approved for inclusion in the Lincolnshire Joint Formulary
Macrogol (polyethylene glycol) 3350 6.9g plus electrolytes, powder for oral solution (CosmoCol Paediatric) (Stirling Anglian)	For the treatment of chronic constipation in children aged from 2 to 11 years. For resolving faecal impaction in children aged 5 years and over.	GREEN Approved for inclusion in the Lincolnshire Joint Formulary
Macrogol (polyethylene glycol) 3350 13.125g plus electrolytes powder for oral solution (Laxido Orange) (Galen)	For chronic constipation and faecal impaction in adults, the elderly and adolescents. Not recommended for children under 12 years.	GREEN Included in the Lincolnshire Joint Formulary
Macrogol (polyethylene glycol) 3350 13.125g plus electrolytes powder for oral solution (Molaxole) (Meda)	For chronic constipation and faecal impaction in adults, the elderly and adolescents. Not recommended for children under 12 years.	GREEN Included in the Lincolnshire Joint Formulary
Macrogol (polyethylene glycol) 3350 13.125g plus electrolytes powder for oral solution (Movicol) (Norgine)	For chronic constipation and faecal impaction in adults, the elderly and adolescents. Not recommended for children under 12 years.	RED-RED No longer included in the Lincolnshire Joint Formulary.
Macrogol (polyethylene glycol) 3350 6.563g plus electrolytes powder for oral solution (Movicol-Half) (Norgine)	For chronic constipation and faecal impaction in adults, the elderly and adolescents. Not recommended for children under 12 years.	RED-RED No longer included in the Lincolnshire Joint Formulary.
Macrogol (polyethylene glycol) 3350 6.563g plus electrolytes, powder for oral solution (Movicol Paediatric) (Stirling Anglian)	For the treatment of chronic constipation in children aged from 2 to 11 years. For resolving faecal impaction in children aged 5 years and over.	RED-RED No longer included in the Lincolnshire Joint Formulary.

Pregabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg (Leceaent) (Actavis UK Ltd)	For use as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of Generalised Anxiety Disorder (GAD) in adults.	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary
Pregabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg (Rewisca) (Consilient Health Ltd)	For use as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of Generalised Anxiety Disorder (GAD) in adults.	GREEN Approved for inclusion in the Lincolnshire Joint Formulary
Quetiapine modified release tablets 50mg, 150mg, 200mg, 300mg and 400mg (Mintreleq XL) (CEB Pharma Ltd)	For the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with major depressive disorder	GREEN Approved for inclusion in the Lincolnshire Joint Formulary. Prescribe by brand. Standard release quetiapine preferred first line.
Rivaroxaban 2.5mg tablets (Xarelto)(Bayer)	For use in combination with aspirin or aspirin and clopidogrel for prevention of atherothrombotic events after acute coronary syndromes in patients with elevated cardiac biomarkers	GREEN Approved for inclusion in the Lincolnshire Joint Formulary for this indication.

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@gemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION